Senior Director Global Value & Real World Evidence
Otsuka Pharmaceutical Development & Commercialization, Inc.
Jeffrey Schein, DrPH, MPH, is an epidemiologist/Outcomes Researcher. Currently, Dr. Schein is in the Global Value & Real-World Evidence group at Otsuka Pharmaceuticals. Initially working in the area of oncology, he then transitioned to the CNS area, focusing on neuropsychiatric symptoms of Alzheimer’s Disease, PTSD, and Attention-Deficit/Hyperactivity Disorder (ADHD).
Prior to his work at Otsuka, Jeffrey had worked for Janssen Pharmaceuticals, where he led a group in Health Economics and Outcomes Research. He worked in several therapeutic areas (e.g., analgesia, anti-infectives, and women’s health), as well as spending about a decade working in the cardiovascular area on anticoagulation and thromboembolism.
Prior to Janssen, Jeffrey had worked for Novartis Pharmaceuticals in Health Economics and Outcomes Research. There, he conducted observational studies in dermatology, neuroscience, respiratory, GI, immunology, dermatology, and bone (osteoporosis).
Jeffrey has experience in the design and conduct of observational studies, burden of illness studies, tools, health surveys, and registries.
Jeffrey has a B.S. in biology from the University of Wisconsin-Madison. He received both his master’s in public health (MPH) and doctorate in public health/epidemiology (DrPH) from Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ) in Piscataway, NJ.